JP2021522180A - ベバシズマブの緩衝製剤を用いる疾患の治療方法 - Google Patents

ベバシズマブの緩衝製剤を用いる疾患の治療方法 Download PDF

Info

Publication number
JP2021522180A
JP2021522180A JP2020557256A JP2020557256A JP2021522180A JP 2021522180 A JP2021522180 A JP 2021522180A JP 2020557256 A JP2020557256 A JP 2020557256A JP 2020557256 A JP2020557256 A JP 2020557256A JP 2021522180 A JP2021522180 A JP 2021522180A
Authority
JP
Japan
Prior art keywords
antibody
preparation
depending
preparation according
retinal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020557256A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021522180A5 (https=
JPWO2019204380A5 (https=
Inventor
ヨナン クリス
ヨナン クリス
デンダムロンビット ウィプーサニー
デンダムロンビット ウィプーサニー
ヒーリー−フライド マーサ
ヒーリー−フライド マーサ
Original Assignee
アウトルック セラピューティクス，インコーポレイティド
アウトルック セラピューティクス，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アウトルック セラピューティクス，インコーポレイティド, アウトルック セラピューティクス，インコーポレイティド filed Critical アウトルック セラピューティクス，インコーポレイティド
Publication of JP2021522180A publication Critical patent/JP2021522180A/ja
Publication of JP2021522180A5 publication Critical patent/JP2021522180A5/ja
Publication of JPWO2019204380A5 publication Critical patent/JPWO2019204380A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2020557256A 2018-04-17 2019-04-17 ベバシズマブの緩衝製剤を用いる疾患の治療方法 Pending JP2021522180A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862658772P 2018-04-17 2018-04-17
US62/658,772 2018-04-17
US201862776686P 2018-12-07 2018-12-07
US62/776,686 2018-12-07
PCT/US2019/027790 WO2019204380A1 (en) 2018-04-17 2019-04-17 Buffered formulations of bevacizumab for use of treating diseases

Publications (3)

Publication Number Publication Date
JP2021522180A true JP2021522180A (ja) 2021-08-30
JP2021522180A5 JP2021522180A5 (https=) 2022-04-22
JPWO2019204380A5 JPWO2019204380A5 (https=) 2022-04-22

Family

ID=66429576

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020557256A Pending JP2021522180A (ja) 2018-04-17 2019-04-17 ベバシズマブの緩衝製剤を用いる疾患の治療方法

Country Status (12)

Country Link
US (1) US20210230261A1 (https=)
EP (1) EP3781199A1 (https=)
JP (1) JP2021522180A (https=)
KR (1) KR20210011923A (https=)
CN (1) CN112543645A (https=)
AU (1) AU2019256289A1 (https=)
BR (1) BR112020021255A2 (https=)
CA (1) CA3097123A1 (https=)
IL (1) IL278041A (https=)
MX (1) MX2020010968A (https=)
SG (1) SG11202010178XA (https=)
WO (1) WO2019204380A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
KR102799807B1 (ko) 2015-12-30 2025-04-24 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
KR102735988B1 (ko) 2019-02-18 2024-12-03 일라이 릴리 앤드 캄파니 치료 항체 제제
CN118718181A (zh) 2019-06-05 2024-10-01 里珍纳龙药品有限公司 用于精确剂量递送的装置及方法
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
KR20220149690A (ko) * 2020-03-04 2022-11-08 상하이 헨리우스 바이오테크, 인크. 베바시주맙을 포함하는 약물 조제용 제제
CN113546172A (zh) * 2020-04-24 2021-10-26 山东大学齐鲁医院 Vegf抑制剂在制备治疗缺氧相关疾病药物中的应用
WO2022006091A1 (en) * 2020-06-29 2022-01-06 Anovent Pharmaceutical (U.S.), Llc Biopharmaceutical formulation of anti-pd-1, anti-pd-l1, and anti-vegfr therapeutic monoclonal antibodies and method for treating nsclc by inhalation
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011528656A (ja) * 2008-07-18 2011-11-24 アラーガン、インコーポレイテッド 萎縮性加齢性黄斑変性の処置方法
JP2013532576A (ja) * 2010-08-05 2013-08-19 フォーサイト・ビジョン フォー・インコーポレーテッド 薬剤送達のための注入用装置および方法
WO2017117202A1 (en) * 2015-12-29 2017-07-06 Oncobiologics, Inc. Buffered formulations of bevacizumab

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11078262B2 (en) * 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
MX379491B (es) * 2014-06-28 2025-03-10 Kodiak Sciences Inc Antagonistas duales de factor de crecimiento derivado de plaquetas (pdgf)/factor de crecimiento endotelial vascular (vegf)
CN106924184B (zh) * 2017-03-29 2020-07-17 烟台大学 一种眼部玻璃体注射用多囊脂质体及其制备方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011528656A (ja) * 2008-07-18 2011-11-24 アラーガン、インコーポレイテッド 萎縮性加齢性黄斑変性の処置方法
JP2013532576A (ja) * 2010-08-05 2013-08-19 フォーサイト・ビジョン フォー・インコーポレーテッド 薬剤送達のための注入用装置および方法
WO2017117202A1 (en) * 2015-12-29 2017-07-06 Oncobiologics, Inc. Buffered formulations of bevacizumab

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 105, JPN6023003080, 2017, pages 127 - 136, ISSN: 0005165110 *
WORLD J DIABETES, vol. 4, no. 2, JPN6023003081, 2013, pages 19 - 26, ISSN: 0005165109 *

Also Published As

Publication number Publication date
CA3097123A1 (en) 2019-10-24
CN112543645A (zh) 2021-03-23
MX2020010968A (es) 2021-01-08
EP3781199A1 (en) 2021-02-24
US20210230261A1 (en) 2021-07-29
IL278041A (en) 2020-11-30
AU2019256289A1 (en) 2020-11-12
SG11202010178XA (en) 2020-11-27
BR112020021255A2 (pt) 2021-02-02
WO2019204380A1 (en) 2019-10-24
KR20210011923A (ko) 2021-02-02

Similar Documents

Publication Publication Date Title
JP2021522180A (ja) ベバシズマブの緩衝製剤を用いる疾患の治療方法
US20260098085A1 (en) Methods for treating age-related macular degeneration
EP3397281B1 (en) Buffered formulations of bevacizumab
KR102589598B1 (ko) 단클론 항체의 제형
JP6920393B2 (ja) 抗体製剤
CN109475597B (zh) 眼用药物组合物
JP7089121B2 (ja) 高濃度の抗ｖｅｇｆ抗体を含有するタンパク質溶液製剤
US20250197486A1 (en) Methods for treating neovascular age-related macular degeneration
JP2025521100A (ja) 抗Ｎｅｃｔｉｎ－４抗体薬物複合体を含む医薬組成物及びその使用
US20130017197A1 (en) Stabilized antibody preparations and uses thereof
EP4438629A1 (en) Multispecific ligand binding molecule and application thereof
JP2025521888A (ja) 抗ｐｄ－ｌ１／抗４－１ｂｂ二重特異性抗体製剤
CN116162148B (zh) 多特异性配体结合分子及其应用
CN116172947A (zh) 一种含特异性结合vegf和ang2的双特异性抗体的药物组合物
RU2791857C2 (ru) Фармацевтическая композиция пембролизумаба и ее применение
WO2022222945A1 (zh) 一种包含抗体融合蛋白的药物组合物及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220414

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220414

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230131

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230424

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231003